Actively Recruiting
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Led by Eisbach Bio GmbH · Updated on 2024-09-19
144
Participants Needed
1
Research Sites
168 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).
CONDITIONS
Official Title
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Recurrent locally advanced or metastatic solid tumors
- Presence of homologous recombination deficient mutations
- Progressed on at least one prior line of treatment or intolerant to additional effective standard therapy
- Measurable disease according to RECIST 1.1 criteria
- Adequate organ and bone marrow function
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Life expectancy greater than 3 months
You will not qualify if you...
- History or evidence of any clinically relevant gastrointestinal disease
- Radiation therapy within 2 weeks prior to enrollment
- Significant cardiovascular disease
- Uncontrolled, active, symptomatic brain metastases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
A
Adrian Schomburg
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here